The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates, of which one drug candidate is in Phase III stage, nine drug candidates are in Phase II stage, four drug candidates are in Phase I stage, four drug candidates are in Pre-Clinical stage and four candidates are in Inactive stage. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis
Insights on pipeline segments
As per the findings of the research, around 44.0% of drug candidates for the treatment of Synovial sarcoma pipeline are being developed to be administered by intravenous route, 28.0% by oral route, 17.0% are undisclosed and 11.0% are to be administered by other routes which includes intradermal and intramuscular.
Major companies collaborate for the development of Synovial sarcoma Pipeline
The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets. A Phase I/II clinical study was undertaken to evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s axitinib (INLYTA) in renal cell carcinoma (RCC). A separate Phase I study was also done to evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566), Pfizer’s investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell proliferation and survival.
Many companies are developing Synovial sarcoma drug candidates in different phases. Adaptimmune Therapeutics plc, Epizyme Inc., Advenchen Laboratories LLC, F. Hoffmann-La Roche AG, Cue Biopharma, Inc., Bayer AG, Merck Sharp & Dohme Corp., Pfizer Inc., Immune Design Inc. and various other companies have their Synovial sarcoma drug candidates in different stages of development.
Other key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc., NewVac LLC, Stemsynergy Therapeutics, Inc. and Immunocore Limited.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)